Local Institution - 0132 — Palm Harbor, Florida

Local Institution - 0132 is a clinical research site located in Palm Harbor, Florida, United States 34684.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Local Institution - 0132 has participated in 1 clinical trials.

Therapeutic areas: Atrial Fibrillation, Atrial Flutter.

Sponsors: Bristol-Myers Squibb.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Palm Harbor

Browse all research sites in Florida · View every site in Palm Harbor

• Advanced Gastroenterology Associates
• Research Site
• Arthritis Center
• The Arthritis Center
• Suncoast Clinical Research
• Arthritis Research of Florida, Inc
• Pfizer Investigational Site
• Novo Nordisk Investigational Site
• GSK Investigational Site
• Palm Harbor Medical Associates
• Novartis Investigative Site
• Arthritis Rsrch of Florida, Inc.

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Local Institution - 0132?

Local Institution - 0132 has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Local Institution - 0132 conducted?

Local Institution - 0132 has 1 clinical trials on record. Their work covers Atrial Fibrillation, Atrial Flutter.

Is Local Institution - 0132 accredited by Crixeo Clinical Trials?

Local Institution - 0132 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Local Institution - 0132?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.